Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Wilms Tumor 1Sarcoma 1Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Filgrastim 10Cyclophosphamide 8X-Rays 6Phantoms, Imaging 6Granulocyte Colony-Stimulating Factor 6Temozolomide 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Ifosfamide 5Carboplatin 5Vincristine 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Melphalan 4Etoposide 4Busulfan 4Topotecan 3Thiotepa 3Stem Cell Transplantation 3Mesna 3Cisplatin 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2sargramostim 2palbociclib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × Glutamic Acid × Sarcoma × Clear all
NCT00369564 2021-08-11

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

University of South Florida

Phase 3 Completed
250 enrolled 10 charts
GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡